Technical Analysis for CVAC - CureVac N.V.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
F | 3.21 | -2.73% | -0.09 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Weak or Absent | Down | Down | Down |
Date | Alert Name | Type | % Chg |
---|---|---|---|
New 52 Week Closing Low | Bearish | 0.00% | |
New 52 Week Low | Weakness | 0.00% | |
Below Lower BB | Weakness | 0.00% | |
Down 3 Days in a Row | Weakness | 0.00% | |
Down 4 Days in a Row | Weakness | 0.00% | |
Lower Bollinger Band Touch | Weakness | 0.00% | |
Oversold Stochastic | Weakness | 0.00% | |
Stochastic Reached Oversold | Weakness | -2.73% | |
Inside Day | Range Contraction | -2.73% | |
Down 3 Days in a Row | Weakness | -2.73% |
Alert | Time |
---|---|
60 Minute Opening Range Breakdown | about 17 hours ago |
Down 3% | about 18 hours ago |
Possible NR7 | about 18 hours ago |
1.5x Volume Pace | about 22 hours ago |
Down 2 % | about 22 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 11/14/2023
CureVac N.V. Description
CureVac B.V., a clinical-stage biopharmaceutical company, engages in developing medicines based on messenger ribonucleic acid. The company's lead clinical programs include CV8102 that is in a Phase I clinical trial for the treatment of various types of solid tumors; and CV7202, which is investigating in a Phase I clinical trial for vaccination against rabies. It is also advancing mRNA vaccine program against coronavirus (SARS-CoV-2), which is in Phase I clinical trial. The company has collaboration and license agreements with GlaxoSmithKline Biologicals SA, Genmab B.V., Boehringer Ingelheim GmbH, and Eli Lilly and Company; development and option agreements with Arcturus Therapeutics, Inc., Acuitas Therapeutics Inc., and CRISPR Therapeutics AG; and a development and intellectual property agreement with Tesla Grohmann Automation GmbH. CureVac B.V. was founded in 2000 and is headquartered in Tübingen, Germany.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Pharmaceutical Solid Tumors Acid Health Care Coronavirus Vaccination CRISPR Rabies Arcturus Therapeutics Genmab
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 12.36 |
52 Week Low | 3.19 |
Average Volume | 824,884 |
200-Day Moving Average | 6.54 |
50-Day Moving Average | 3.55 |
20-Day Moving Average | 3.38 |
10-Day Moving Average | 3.34 |
Average True Range | 0.16 |
RSI (14) | 36.71 |
ADX | 18.19 |
+DI | 15.05 |
-DI | 20.52 |
Chandelier Exit (Long, 3 ATRs) | 3.17 |
Chandelier Exit (Short, 3 ATRs) | 3.67 |
Upper Bollinger Bands | 3.55 |
Lower Bollinger Band | 3.22 |
Percent B (%b) | -0.02 |
BandWidth | 9.70 |
MACD Line | -0.08 |
MACD Signal Line | -0.09 |
MACD Histogram | 0.0048 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 3.38 | ||||
Resistance 3 (R3) | 3.39 | 3.34 | 3.35 | ||
Resistance 2 (R2) | 3.34 | 3.30 | 3.34 | 3.34 | |
Resistance 1 (R1) | 3.28 | 3.28 | 3.26 | 3.27 | 3.33 |
Pivot Point | 3.23 | 3.23 | 3.22 | 3.23 | 3.23 |
Support 1 (S1) | 3.17 | 3.19 | 3.15 | 3.16 | 3.09 |
Support 2 (S2) | 3.12 | 3.17 | 3.12 | 3.08 | |
Support 3 (S3) | 3.06 | 3.12 | 3.07 | ||
Support 4 (S4) | 3.05 |